Clinical management of BRCA1 and BRCA2 mutation carriers.
The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.
Domchek
S M
SM
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. susan.domchek@uphs.upenn.edu
Weber
B L
BL
D001943:Breast Neoplasms / Q000235:genetics* / Q000517:prevention & control; D005260:Female; D019398:Genes, BRCA1; D006580:Genetic Carrier Screening; D006801:Humans; D009154:Mutation; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000517:prevention & control; D040242:Risk Reduction Behavior